GeoVax Labs Files 8-K: Material Agreement & Equity Sale

TL;DR

GeoVax Labs inked a deal, sold some stock, and filed financials. Big moves happening.

AI Summary

On July 11, 2024, GeoVax Labs, Inc. entered into a material definitive agreement related to the unregistered sale of equity securities. The company also made a Regulation FD disclosure and filed financial statements and exhibits.

Why It Matters

This filing indicates a significant event for GeoVax Labs, Inc., potentially involving new financing or strategic partnerships through the sale of equity.

Risk Assessment

Risk Level: medium — The filing involves unregistered sales of equity securities, which can sometimes indicate financial needs or dilution concerns for existing shareholders.

Key Players & Entities

• GeoVax Labs, Inc. (company) — Registrant
• July 11, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — h registered Common Stock , par value $0.001 per share GOVX The Nasdaq Capital Ma
• $2.86 — ublic offering price for each Share was $2.86 and the public offering price for each
• $2.85999 — g price for each Pre-Funded Warrant was $2.85999. The Pre-Funded Warrants have an exerci
• $0.0001 — nded Warrants have an exercise price of $0.0001 per share, are exercisable immediately
• $2,836,000 — f the Common Warrants, is approximately $2,836,000. The Company intends to use the net pro
• $0.00001 — exercised at a nominal consideration of $0.00001 per share of Common Stock any time unti

Filing Documents

• govx20240711_8k.htm (8-K) — 40KB
• ex_697615.htm (EX-4.1) — 87KB
• ex_697669.htm (EX-4.2) — 111KB
• ex_697646.htm (EX-5.1) — 11KB
• ex_697616.htm (EX-10.1) — 147KB
• ex_697617.htm (EX-10.2) — 201KB
• ex_697618.htm (EX-99.1) — 12KB
• ex_697646img001.jpg (GRAPHIC) — 3KB
• logo.jpg (GRAPHIC) — 13KB
• wbdcontact.jpg (GRAPHIC) — 12KB
• wbdlogo.jpg (GRAPHIC) — 17KB
• wbdsite.jpg (GRAPHIC) — 6KB
• 0001437749-24-022656.txt ( ) — 972KB
• govx-20240711.xsd (EX-101.SCH) — 4KB
• govx-20240711_def.xml (EX-101.DEF) — 13KB
• govx-20240711_lab.xml (EX-101.LAB) — 17KB
• govx-20240711_pre.xml (EX-101.PRE) — 13KB
• govx20240711_8k_htm.xml (XML) — 5KB

01

Item 1.01 Entry into a Material Definitive Agreement. On July 11, 2024, GeoVax Labs, Inc. (the "Company") entered into a placement agency agreement (the "Placement Agency Agreement") with Roth Capital Partners, LLC (the "Placement Agent") and a securities purchase agreement (the "Purchase Agreement") with a purchaser pursuant to which the Company agreed to sell, in a registered direct offering (the "Offering"), an aggregate of (i) 458,632 shares (the "Shares") of the Company's common stock, $0.001 par value per share (the "Common Stock"), and (ii) pre-funded warrants to purchase up to an aggregate of 626,368 shares of Common Stock (the "Pre-Funded Warrants," and the Shares issuable upon exercise thereof, the "Pre-Funded Warrant Shares"). In a concurrent private placement, the Company offered common warrants to the purchaser, with each warrant exercisable to purchase one share of Common Stock (the "Common Warrants"), with two Common Warrants to accompany each share of Common Stock or Pre-Funded Warrant sold in the Offering, and to purchase in the aggregate up to 2,170,000 shares of Common Stock (the "Common Warrant Shares"). The public offering price for each Share was $2.86 and the public offering price for each Pre-Funded Warrant was $2.85999. The Pre-Funded Warrants have an exercise price of $0.0001 per share, are exercisable immediately and may be exercised at any time until exercised in full. The Common Warrants have an exercise price of $2.86 per share, are immediately exercisable upon the receipt of stockholder approval and will expire five years from the date of such stockholder approval. The net proceeds of the Offering, after deducting the placement agent's fees and expenses and other offering expenses payable by the Company and excluding the net proceeds, if any, from the exercise of the Common Warrants, is approximately $2,836,000. The Company intends to use the net proceeds from the Offering for working capital and general corporate purposes. The Of

02

Item 3.02 Unregistered Sales of Equity Securities. The Company has agreed to issue the Common Warrants pursuant to the exemption from the registration requirements of the Securities Act, available under Section 4(a)(2) and/or Rule 506(b) of Regulation D promulgated thereunder and intends to issue the Common Warrant Shares pursuant to the same exemption. The description of the Common Warrants under Item 1.01 of this Form 8-K is incorporated by reference herein. The Form of Common Warrant has been filed as an exhibit to this Form 8-K and are incorporated by reference herein.

01

Item 7.01 Regulation FD Disclosure. On July 11, 2024, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits . The following Exhibits are being filed or furnished, as applicable, with this Current Report on Form 8-K. Exhibit No. Description 4.1 Form of Pre-Funded Warrant 4.2 Form of Common Warrant 5.1 Opinion of Womble Bond Dickinson (US) LLP 10.1 Form of Placement Agency Agreement 10.2 Form of Purchase Agreement 23.1 Consent of Womble Bond Dickinson (US) LLP (contained in Exhibit 5.1) 99.1 Press Release dated July 11, 2024, announcing the pricing of the Offering 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GeoVax Labs, Inc. July 12, 2024 By: /s/ Mark W. Reynolds Name: Mark W. Reynolds Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR